Werewolf Therapeutics Inc
HOWL1.490USD
+0.040+2.76%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
67.55MCap. mercado
PérdidaP/E TTM
Más Datos de Werewolf Therapeutics Inc Compañía
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.
Información de la empresa
Símbolo de cotizaciónHOWL
Nombre de la empresaWerewolf Therapeutics Inc
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoDr. Daniel J. (Dan) Hicklin, Ph.D.
Número de empleados46
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 30
Dirección200 Talcott Avenue
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Teléfono16179520555
Sitio Webhttps://werewolftx.com/
Símbolo de cotizaciónHOWL
Fecha de salida a bolsaApr 30, 2021
Director ejecutivoDr. Daniel J. (Dan) Hicklin, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Dr. Chulani Karunatilake, Ph.D.
Dr. Chulani Karunatilake, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Michael A. (Mike) Sherman
Mr. Michael A. (Mike) Sherman
Independent Director
Independent Director
--
--
Dr. Luke Evnin, Ph.D.
Dr. Luke Evnin, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Randi Isaacs, M.D.
Dr. Randi Isaacs, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Steven Bloom
Mr. Steven Bloom
Chief Business Officer
Chief Business Officer
--
--
Dr. Michael B. Atkins, M.D.
Dr. Michael B. Atkins, M.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. (Dan) Hicklin, Ph.D.
Dr. Daniel J. (Dan) Hicklin, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Alon Lazarus, Ph.D.
Dr. Alon Lazarus, Ph.D.
Independent Director
Independent Director
--
--
Dr. Meeta Chatterjee, Ph.D.
Dr. Meeta Chatterjee, Ph.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Director
Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
14.61%
MPM Capital Inc.
9.42%
MPM BioImpact LLC
5.27%
BofA Global Research (US)
4.66%
Arkin Bio Ventures LP
4.48%
Otro
61.57%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
14.61%
MPM Capital Inc.
9.42%
MPM BioImpact LLC
5.27%
BofA Global Research (US)
4.66%
Arkin Bio Ventures LP
4.48%
Otro
61.57%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
16.68%
Venture Capital
14.61%
Research Firm
6.19%
Investment Advisor
6.17%
Hedge Fund
5.54%
Corporation
4.48%
Individual Investor
1.48%
Otro
44.86%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
157
30.29M
67.51%
-6.30M
2025Q1
159
30.37M
68.02%
-6.24M
2024Q4
157
31.11M
69.81%
-7.22M
2024Q3
161
35.12M
80.23%
-3.46M
2024Q2
148
35.04M
80.49%
-1.98M
2024Q1
150
35.07M
81.79%
+2.03M
2023Q4
134
30.53M
84.54%
+2.78M
2023Q3
139
30.67M
86.21%
+2.11M
2023Q2
142
30.83M
86.75%
+2.42M
2023Q1
141
30.79M
87.31%
+3.80M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
6.68M
14.89%
+536.43K
+8.73%
May 14, 2025
MPM Capital Inc.
4.31M
9.6%
--
--
Apr 14, 2025
MPM BioImpact LLC
2.41M
5.37%
+20.80K
+0.87%
Mar 31, 2025
BofA Global Research (US)
2.10M
4.69%
+24.27K
+1.17%
Mar 31, 2025
Arkin Bio Ventures LP
2.05M
4.56%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.51M
3.36%
+88.47K
+6.23%
Mar 31, 2025
Millennium Management LLC
784.62K
1.75%
+188.33K
+31.58%
Mar 31, 2025
Hicklin Daniel J
647.05K
1.44%
--
--
Apr 14, 2025
Sphera Funds Management Ltd.
626.81K
1.4%
--
--
Mar 31, 2025
DC Funds, LP
589.10K
1.31%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
DFA Dimensional US Core Equity Market ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
